Key result
In chronic heart failure, metabolic remodeling shifts from early carbohydrate utilization to later fatty acid oxidation, with improving metabolic capability being more significant than substrate choice.
Metabolic remodeling in chronic heart failure involves dynamic shifts in substrate utilization, highlighting metabolic capability as a potential therapeutic target.
May support targeting metabolic capability in chronic HF; leaves open need for prospective trials to guide therapy.
Although the management of chronic heart failure (CHF) has made enormous progress over the past decades, CHF is still a tremendous medical and societal burden. Metabolic remodeling might play a crucial role in the pathophysiology of CHF. The characteristics and mechanisms of metabolic remodeling remained unclear, and the main hypothesis might include the changes in the availability of metabolic substrate and the decline of metabolic capability. In the early phases of the disease, metabolism shifts toward carbohydrate utilization from fatty acids (FAs) oxidation. Along with the progress of the disease, the increasing level of the hyperadrenergic state and insulin resistance cause the changes that shift back to a greater FA uptake and oxidation. In addition, a growing body of experimental and clinical evidence suggests that the improvement in the metabolic capability is likely to be more significant than the selection of the substrate.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) conducted a review in chronic heart failure. In chronic heart failure, metabolic remodeling shifts from early carbohydrate utilization to later fatty acid oxidation, with improving metabolic capability being more significant than substrate choice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: